Consequently, these phosphorylated residues have emerged as focal points in the development of immunotherapies targeting tau’s aggregation and its disease-causing properties, targeting efforts towards mitigating the adverse effects of tau phosphorylation in AD. Here, MAPT is linked to Alzheimer disease.